ADHD Advisory Committee Wants FDA-Defined Standards Before Clearing Abuse-Deterrent Stimulant Label
Executive Summary
Panel on Arbor Pharmaceuticals' reformulated stimulant highlights the risks of trying to craft a new labeling niche without any FDA guidance or endorsement of the idea.
You may also be interested in...
BIO 2021 Notebook: Biogen CEO On Corporate Responsibility
News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains.
BIO 2021 Notebook: Biogen CEO On Corporate Responsibility
News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains.
Tweaks To CBO Model May Add Another Hurdle To Congressional Drug Pricing Reform Effort
New model suggests extra hit for accelerated approval drugs. But despite Congress and President Biden looking toward a scaled-backed version of the Build Back Better reconciliation package, many health care politics experts believe drug price negotiation will make it into law this year.